Participating in the Vietnam International Medical and Pharmaceutical Exhibition (Pharmedi Vietnam 2024), held from September 11–14, 2024 at the Saigon Exhibition and Convention Center (SECC), Aikya Pharmaceutical Joint Stock Company (AIKYA)—one of Vietnam’s leading pharmaceutical corporations—received strong attention and high praise from Ministry of Health leaders as well as domestic and international partners.
Speaking at the opening ceremony on September 11, Assoc. Prof. Dr. Nguyễn Thị Liên Hương, Deputy Minister of Health, emphasized that over the years, the Vietnam International Medical Exhibition has served as an important platform for enterprises to showcase their products, enhance investment cooperation, and facilitate technology exchange and transfer. These efforts, she noted, contribute significantly to the application of advanced technologies in medical examination, treatment, and in improving public health.
Deputy Minister of Health Visits AIKYA Pharmaceutical’s Exhibition Booth at the Vietnam International Medical Exhibition
Deputy Minister of Health Visits AIKYA Booth, Highlights Achievements in Pharmaceutical Innovation and Global Collaboration
As part of her visit to the Vietnam International Medical Exhibition, Deputy Minister of Health Assoc. Prof. Dr. Nguyễn Thị Liên Hương toured multiple booths, including AIKYA Pharmaceutical’s exhibition area, where she was given a brief overview of the company’s key achievements in pharmaceutical manufacturing, technological innovation, and international cooperation.
AIKYA proudly showcased several of its high-quality, market-leading products that have earned prestigious national recognition, including Orenko, Phariton TVP, and the Mebiphar 3D Medical Mask—products honored with the Vietnam National Brand and Vietnamese Star Pharma (Ngôi sao thuốc Việt) titles.
A highlight of the exhibition was the introduction of Vietnam’s largest High-Tech Pharmaceutical Industrial Cluster, which is being developed by AIKYA. This ambitious project drew significant attention from international partners, particularly from India, Japan, China, and Myanmar. Once completed, the facility will have an annual production capacity of 3.5 billion product units, substantially enhancing supply chain resilience, meeting domestic healthcare demands, and boosting AIKYA’s export capabilities and competitiveness on the global stage.
The AIKYA brand and its products recognized with the Vietnam National Brand and Vietnamese Star Pharma titles have attracted customers and partners to promote collaboration.
“We believe that with our long-standing reputation in the Vietnamese pharmaceutical market, along with a diverse range of high-quality products and the ongoing development of our High-Tech Pharmaceutical Industrial Complex, AIKYA’s booth is one of the highlights at the Pharmedi VietNam 2024 exhibition,” said Mr. Nguyễn Lê Phương, Marketing Director of AIKYA Pharmaceutical Company.
AIKYA is proud to be one of the leading pharmaceutical groups in Vietnam specializing in the research, development, manufacturing, and trading of medicines, medical devices, and healthcare products.
AIKYA currently has three member companies: TV.PHARM, MEBIPHAR, and S.PHARM, as well as managing centers including the ALPHA LAB product research and development center and the ALPHA TRADE distribution center. AIKYA owns four manufacturing complexes located in Trà Vinh, Ho Chi Minh City, and Sóc Trăng, with three complexes comprising a total of 11 production lines that meet GMP-WHO standards, and the AIKYA EUROPA pharmaceutical plant that adheres to GMP-EU standards.
At the event, AIKYA showcased a variety of standout products across different categories, including: pain relievers and fever reducers, cardiovascular and diabetes treatments, antibiotics and anti-inflammatory drugs, respiratory, neurological and cerebral circulation products, digestive treatments, and health supplements.
AIKYA’s booth at the Vietnam International Medical Exhibition.
Among these are products that have won the National Brand Award and the Vietnamese Medicine Star Award, such as the antibiotic Orenko, the pain-relieving and fever-reducing product line Travicol, the anti-diabetic drug Glucofast, the health supplement Phariton TVP, and the Mebiphar 3D Mask medical mask.
Pharmedi VietNam 2024 is the largest international healthcare event in Vietnam, highly regarded by industry professionals. The exhibition gathers 1,000 booths from businesses in 25 countries and territories, with an estimated 15,000 professional visitors (B2B).
Like other businesses participating in Pharmedi Vietnam 2024, AIKYA believes the exhibition will provide new opportunities for companies to meet, exchange technology, and enhance cooperation with domestic and international partners and investors. This will contribute to boosting business operations and actively participating in the protection and improvement of public health.
